
Intellia Therapeutics (NTLA) Stock Forecast & Price Target
Intellia Therapeutics (NTLA) Analyst Ratings
Bulls say
Intellia Therapeutics is positioned for a positive outlook due to its innovative use of Crispr/Cas9 technology to address high unmet medical needs in genetically defined diseases, which enhances its market potential. The company's financial model anticipates a significant reduction in operating expenses, projected to decrease from $600 million annually to $150 million by 2034, contributing to improved profitability. Additionally, revisions to the expected penetration rates for its therapies NTLA-2001 and NTLA-2002 have been increased to 10% from a previous 3.5%, signaling confidence in the therapeutics' market adoption amid a competitive landscape.
Bears say
Intellia Therapeutics exhibits a significantly negative outlook due to a 95% decline from its all-time highs, suggesting a waning investor confidence in the gene editing sector as a whole. The company faces substantial clinical and regulatory risks, including potential delays in trial initiation and the possibility that therapies may not gain approval from global regulatory agencies, which could further impair financial performance. Additionally, there exists a heightened "headline risk" whereby negative news surrounding gene editing technology, even if unrelated to Intellia’s specific efforts, could adversely affect the company's stock value.
This aggregate rating is based on analysts' research of Intellia Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Intellia Therapeutics (NTLA) Analyst Forecast & Price Prediction
Start investing in Intellia Therapeutics (NTLA)
Order type
Buy in
Order amount
Est. shares
0 shares